MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the …
SAN JOSE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of …
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for …
TAMPA, Fla., May 09, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced purchasing Solana Tokens (SOL) for approximately $1.5 million as part of the …
Glasgow, May 09, 2025 (GLOBE NEWSWIRE) -- Introduction: Best Bodybuilding Supplements to Accelerate Muscle Growth—Including Legal Steroids In the competitive world of fitness and bodybuilding, every rep, every gram of protein, and every supplement you take …
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. …
Dr. Mohana Rao Patibandla's Quiet Revolution in Neurosurgery GUNTUR, ANDHRA PRADESH, INDIA, May 9, 2025 /EINPresswire.com/ -- Renowned Neurosurgeon Dr. Rao Chooses Guntur Over Global Metropolises, Revolutionizing Local Healthcare Dr. …
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Garuda Therapeutics (“Garuda”), a biotechnology company developing off-the-shelf hematopoietic stem cell (HSC) therapies, today announced that it has changed its name to Stratus Therapeutics, Inc. (“ …
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Interim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to …
SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today …
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy …
Guardian Recovery, a leading provider of substance use disorder and mental health treatment announces the grand opening of Southern Maine Recovery Center. WESTBROOK, ME, UNITED STATES, May 8, 2025 /EINPresswire.com/ -- Guardian Recovery, a …
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision …
Tigris Trial Enrollment completed Topline results expected to be released in August 2025 Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical …
Guardian Recovery announces the appointment of Ross Bacon as Vice President of Business Development bringing valuable expertise to support continued growth. DELRAY BEACH, FL, UNITED STATES, May 8, 2025 /EINPresswire.com/ -- Guardian Recovery …
Guardian Recovery announces the rebranding of two key treatment facilities in South Florida to further unify its expansive network of treatment facilities. DELRAY BEACH, FL, UNITED STATES, May 8, 2025 /EINPresswire.com/ -- Guardian Recovery …
First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating …
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master …
Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33 …
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief …
